European Commission’s drive to launch a medical device created in the Hospital and the Germans Trias i Pujol Research Institute to improve the diagnosis and prognosis of the acute ischaemic stroke

The care and treatment provided to people who suffer an ischemic stroke can improve thanks to a technology developed in Catalonia. This is the purpose of Time is Brain (TiB), a start-up that arose from a scientific project carried out by the Hospital and the Germans Trias i Pujol Research Institute (IGTP), which has just received an investment by the European Union of almost 6 million euros in order for the hospitals to count on a pioneering device to manage acute ischaemic stroke.

Two studies from the Immunology group on autoimmunity and hematopoietic stem cells show promising therapeutic potential

The first study, published in Nanomedicine: Nanotechnology, Biology and Medicine, seeks a strategy to safely and definitevely restore self-tolerance in autoimmune diseases; the second, in Archivum Immunologiae et Therapiae Experimentalis, bets on making the most of umbilical cord blood cells, key against hematological diseases

Two IGTP projects, financed with 1.6 million euros by the European Commission

The European Commission has granted two projects to the IGTP within the HORIZON programme, which add up to a total of 1,670,346 euros in funding and deal with the preclinical development of immunotherapies.

About thirty healthcare and research professionals from institutions belonging to the Can Ruti Campus, among the world’s most renowned scientists

Antoni Bayés, Pere Joan Cardona, Magí Farré, Miquel Àngel Gassull, Manel Puig-Domingo, Manuel Perucho and Jordi Barretina, all past and present members of IGTP staff together with nearly twenty other affiliated researchers and medical staff from Can Ruti Campus institutions -many affiliated to the IGTP- are included in Elsevier's Scopus list, composed of the 200,000 most renowned researchers worldwide.

A scientific project led by Beatriz Mothe receives the Young Researchers Award from the AstraZeneca Foundation

• The project aims to contribute to the design of more universal therapies for COVID-19 with efficacy in more vulnerable groups, such as people with immunosuppression
• The awards are an initiative to promote the development and consolidation of young scientific talent in Spain

In vitro development of a new personalized therapy for patients with neurofibromatosis type 2

Researchers from the Clinical Genomics group of the Germans Trias i Pujol Research Institute (IGTP) and the Genetics Service of the Germans Trias Hospital (HUGTiP) have developed a new in vitro therapy to recover part of the function encoded by the gene NF2, which, when altered, induces the development of neurofibromatosis type 2. The study has been published in the prestigious journal Molecular Therapy Nucleic Acids.

Reformulating clinical internships: an innovative teaching approach at IGTP

The Germans Trias i Pujol Research Institute (IGTP) and the Germans Trias Hospital participate in the HEAL project, which is funded through the Erasmus+ programme. HEAL is an ambitious project aimed at reformulating the way clinical internships currently take place in hospitals.

A study of more than 750 healthcare professionals confirms that antibodies persist 17 months after having suffered from COVID-19

• Research has also confirmed that people who suffered from the disease in a serious way generate more antibodies than those who had moderate and mild effects.
• The results of this study show significant differences in the generation of antibodies between men and women on day 30 of infection and for all antibodies measured.
• This is one of the largest studies carried out to date in Catalonia, both in terms of the volume of participants and the length of follow-up.

Open doors morning for the second year of baccalaureate students of the Col·legi Cultural de Badalona

Yesterday morning, a group of second year of scientific baccalaureate students of the Col·legi Cultural de Badalona visited the IGTP. They had the opportunity to see the facilities and learn about basic research pratices.

Breaz Medical, a new spin-off of IGTP for the timely diagnosis of COPD

• Timely diagnosis is crucial to detect chronic obstructive pulmonary disease (COPD), an underdiagnosed entity in 75% of cases
• Breaz is developing a fast and precise testing device to improve the diagnosis and prognosis of this respiratory disease